Latest News and Press Releases

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) COVID-19 Clinical Programme Update SNG001 given Fast Track designation and IND cleared by the US FDAPhase III trial design adapted which...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020 Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients SNG001 well tolerated in this older population...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients Patients who received SNG001 had a 79% lower...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients Patients who received SNG001 had a 79%...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Southampton, UK – 28 May 2020: Synairgen plc (LSE: SNG), the...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Update on expanded SG016 trial for patients with COVID-19:Synairgen initiates dosing of SNG001 in home setting to treat patients earlier in...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Preliminary results for the year ended 31 December 2019 Southampton, UK – 26 May 2020: Synairgen plc (LSE: SNG), the respiratory drug...

Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen to start trial of SNG001 in COVID-19 imminently Southampton, UK – 18 March 2020: Synairgen plc (LSE: SNG), the respiratory drug...